RECRUITING

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Description

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Conditions

Cancer, MetastaticCancerCancer of PancreasCancer of LiverCancer of StomachCancer LiverCancer of RectumCancer of KidneyCancer of EsophagusCancer of CervixCancer of ColonCancer of LarynxCancer, LungCancer, BreastCancer, AdvancedCancer ProstateCancer of NeckCancer of SkinNeuroendocrine TumorsCarcinomaMismatch Repair DeficiencyBRCA Gene RearrangementNon Hodgkin LymphomaLeukemiaNon Small Cell Lung CancerCholangiocarcinomaGlioblastomaCentral Nervous System TumorMelanomaUrothelial CarcinomaBladder CancerOvarian CancerEndometrial CancerTesticular CancerBreast CancerCOVIDMyelofibrosisMyeloproliferative NeoplasmMyeloproliferative DisordersFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic Syndromes
Talk to us

Related Conditions:

Cancer, MetastaticCancerCancer of PancreasCancer of LiverCancer of StomachCancer LiverCancer of RectumCancer of KidneyCancer of EsophagusCancer of CervixCancer of ColonCancer of LarynxCancer, LungCancer, BreastCancer, AdvancedCancer ProstateCancer of NeckCancer of SkinNeuroendocrine TumorsCarcinomaMismatch Repair DeficiencyBRCA Gene RearrangementNon Hodgkin LymphomaLeukemiaNon Small Cell Lung CancerCholangiocarcinomaGlioblastomaCentral Nervous System TumorMelanomaUrothelial CarcinomaBladder CancerOvarian CancerEndometrial CancerTesticular CancerBreast CancerCOVIDMyelofibrosisMyeloproliferative NeoplasmMyeloproliferative DisordersFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic Syndromes

Study Overview

On this page

Study Details

Study overview

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Condition
Cancer, Metastatic
Intervention / Treatment

-

Contacts and Locations

New York

Massive Bio, Inc, New York, New York, United States, 10006

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pts with solid and hematological malignancies;
  • * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
  • * Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
  • * ECOG PS \> 2;
  • * Abnormal organ function;
  • * Hospice enrollment

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massive Bio, Inc.,

Selin Kurnaz, PhD, PRINCIPAL_INVESTIGATOR, Massive Bio, Inc.

Study Record Dates

2027-06